Overview

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics. It will also provide important information about the appropriate doses to be used in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044 alone and in combination with other anti-diabetic agents.
Phase:
Phase 2
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.